A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs BNC 210 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors Bionomics
- 11 Apr 2017 Treatment arms has been increases from 2 to 4 and patients number also increases.
- 11 Apr 2017 Planned number of patients changed from 160 to 192.
- 18 Oct 2016 New trial record